Baird Financial Group
BRNS

Baird Financial Group’s Barinthus Biotherapeutics BRNS Stock Holding History

Baird Financial Group’s Portfolio BRNS Stock Details BRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$60.3K Hold
105,961
– – ﹤0.01% 1819
2025
Q4 		$74.2K Sell
105,961
-1,500
-1% -$1.5K ﹤0.01% 1779
2025
Q3 		$134K Sell
107,461
-85,000
-44% -$106K ﹤0.01% 1760
2025
Q2 		$179K Buy
192,461
+100,000
+108% +$87.4K ﹤0.01% 1717
2025
Q1 		$89.9K Hold
92,461
– – ﹤0.01% 1724
2024
Q4 		$112K Hold
92,461
– – ﹤0.01% 1714
2024
Q3 		$110K Sell
92,461
-175,244
-65% -$235K ﹤0.01% 1702
2024
Q2 		$375K Buy
267,705
+100,000
+60% +$226K ﹤0.01% 1485
2024
Q1 		$399K Sell
167,705
-28,591
-15% -$80.7K ﹤0.01% 1466
2023
Q4 		$724K Hold
196,296
– – ﹤0.01% 1235
2023
Q3 		$607K Hold
196,296
– – ﹤0.01% 1266
2023
Q2 		$404K Buy
196,296
+17,000
+9% +$40.3K ﹤0.01% 1422
2023
Q1 		$402K Buy
179,296
+86,835
+94% +$242K ﹤0.01% 1398
2022
Q4 		$217K Buy
+92,461
New +$235K ﹤0.01% 1578

Other funds holding BRNS

MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
GP
GLR Partners Columbia, Maryland $215M AUM
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JHU
Johns Hopkins University Baltimore, Maryland $1.38B AUM 9.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

Baird Financial Group's BRNS Position: Q1 2026 in Review

Baird Financial Group held its Barinthus Biotherapeutics (BRNS) position steady in Q1 2026 at 105,961 shares worth $60.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1819.

Baird Financial Group first reported a position in BRNS in Q4 2022 and has held it in 14 quarters since. The position peaked at $724K in Q4 2023. 14 funds tracked by Wall St. Rank hold BRNS as of Q1 2026.

  • Baird Financial Group held 105,961 shares of Barinthus Biotherapeutics worth $60.3K as of Q1 2026.
  • Baird Financial Group left its Barinthus Biotherapeutics share count unchanged in Q1 2026.
  • Barinthus Biotherapeutics made up ﹤0.01% of Baird Financial Group's portfolio in Q1 2026, its #1819 holding.
  • Baird Financial Group first reported a position in Barinthus Biotherapeutics in Q4 2022 and has held it in 14 quarters since.
  • Baird Financial Group's Barinthus Biotherapeutics position peaked at $724K in Q4 2023.
  • 14 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q1 2026.

Based on Baird Financial Group's 13F filing for Q1 2026, filed 14 May 2026.